Chief Thanks, operator. Officer. quarter on third am Welcome the joined to our everyone the call call by Financial for XXXX. morning I earnings of this our Semb, Tara
quick the provide third for COVID-XX of begin revenue you I will of a of a the pandemic results our for results. me summary call. impact with with a today’s review our quarterly the on including agenda quarter, Let
strategy. provide Tara initiatives review our Following some four recent we our this on discussion, I of as have made our the you with highlights part and provide operational results, you update are progress will pursuing with our we of on financial as for a an assumptions the as detailed well modeling considerations quarter. fourth then financial and our growth in long-term performance will
sales decreased while decreased year-over-year total geographic From of decrease quarter to $X.X to of some a thoughts review the $X our sales standpoint, results. on with for additional XXXX with representing year-over-year. reported revenue near-term X% XXXX, of outlook conclude third get quarter will our international questions. for year-over-year million. revenue call U.S. open total the We third I $X.X With before a for our of long-term XX% remarks, we the million, Tara’s that, million Following of total started the and let’s X%
million. $X.X by business, year-over-year were In terms segments, essentially in total in in offset year-over-year driven OEM business at our year-over-year. of year-over-year, impact COVID-XX business partially each was a utilization decreased strong million sales in Energy the our on in based XX% revenue XX% global sales business, demand XX% Advanced Despite handpiece were from Energy in handpiece recovery trends by cosmetic Most of generator decline which Advanced our Energy and revenue we increase to our our growth decline sales surgery sales capital performance The global $X.X revenue XX% was Advanced saw U.S. by we QX an sales, of continued in by flat the of that in progress. the of continued the XX% our our driven pleased notably, to in improving was as year-over-year customers.
Specifically, we saw growth U.S. handpiece year-over-year. XX% sales in
a consultations, period. cases backlog Many virtual were the entered spring. all as more very working reported at pandemic past this we trends U.S. detail, of of building Looking during reported in by handpiece to employing over closed offices strong in existing as third our pipelines why COVID caused the nearly result U.S. also our this practices, customers busy accommodate were have quarter, the their
As a was for result the in an of U.S. these our clinician exceptionally strong customers dynamics, month July
these of mid-August, both benefited we July dynamics growth we as from cases. accounts By backlog, that office reporting accounts their conference were able to softer to accommodate of in their prior to extending QX additional comparison for adding a call. that work with through also schedule our believe in order many they performance were their year discussed on majority Our these hours days the
of from which feedback weeks underlying we our our are trends. reporting Outside handpieces characterize of a of geographic through many remains difficult Renuvion This recent business U.S., in customers, backlog different world, have of their to consistent each of quarter, around to based continued it utilization we throughout after increased rates primary improving who is the given trends. received recovery working positive see the with cases. strong remaining Importantly, patient as for the our view demand volumes of the regions that U.S. sign we the
encouraging experienced the our handpiece improved demand during markets On in side, the primary third quarter. we OUS
have However, to of third the the recovery seen saw market, still lag U.S. improving that in the sales behind the were year-over-year while we the handpiece and continues in international trends demand quarter trends handpieces down we in
internationally. capital the early in equipment remains the stages U.S. front, the recoveries, purchasing overall On the environment and of in both
technology are the surgeon pandemic. reluctant We customers new see practices business uncertainty COVID-related potential disruption to and given overhang of future by in to their the invest that for created continue new the continued the
importantly, adoption. the continue access clinician impact in-person like rep the selling and of restrictions clinician to and lack tradeshows to ability More on opportunities, COVID drive our events new
decline that our year-over-year in from registrations OUS securing new product had experienced generator in third recent sale our global the success of we authorizing has team Helium While the Technology performance benefited the quarter, countries. sales Plasma in during our
with XX% that Advanced orders by and in orders business. saw Taiwan to the with the we the QX. Brazil the international Advanced global decrease we sequential during improvements sales quarter summary, initial and in trends Energy to registrations Energy are new report to increase our have of these continued helped year-over-year These Thailand. Australia. pleased in our X and in in very countries overall In COVID-XX, quarter to of shipped orders that impact and the product of despite third offset business handpiece encouraged this we receipt the In the year, orders shipped X are of initial Australia, announced During QX, pleased that we second am Brazil along recall I additional and new countries
through and adept supporting their working their after the that Our open, team becoming managing excellent The in is sustained we doing see continue distributors. to remain patients. while global their serve this our prioritizing our lastly, we new added to the majority international of of And and benefit practices while evidence Advanced the pleased U.S. the are backlog of and we capital safety more in patient OUS accounts sales surgeon sales existing of job from an stages year. we both in Energy performance U.S. are seeing our early efficiently, improvement that equipment in countries customers of volumes in recovery health at purchasing,
surgery of Medical on of procedures sell during us After restrictions indications market the Turning the made clinical in quarter, quarter, progress very pleased of starting continue for studies, progress the operational achievement to to key second which use lifted the to of discussion Renuvion to U.S. and both long-term in milestones our initiatives to skin considerable with our our procedures. targeted to new to clinical two specific respect four the progress first resurfacing elective during to IDE on growth position for were of will support intended our initiative these new we make we cosmetic strategic with on pursuit enable dermal the team and laxity pursue market, our that announce indications our procedures. are are Apyx Today, for studies.
completed announce study Renuvion First in for and resurfacing of that excited procedures. the our evaluating enrollment we week last technology I use foremost, clinical dermal have am to
in study Renuvion use progress in and make evaluating the neck laxity procedures of skin our in first the to submental the continue also phase We of IDE region.
to the focused the I reminder, safety that pleased collecting FDA data our the completing the for completed X-month X-month and working safety look to on be to As begin X-month FDA submitted safety with Phase requirements review. concluded that we week, X a FDA data Phase data am is to Phase in we to review FDA completed met review. announce our X. and of X Phase We to their for submitted Last safety study. enrollment of our X forward
U.S. on commercial expanding regulatory obtaining by clearance in focused are strategy, new our Technology we our our footprint for countries. to addition internationally Helium Plasma regulatory In
of pleased quarter, to our during and Brazil, earlier, to new regulatory with and registrations Israel, we Thailand in mentioned the and expanded receive profile. these market Latvia second new and in to products benefit In addition I international X of sell expect product the growth Australia, of long-term countries approval As Lithuania. countries, each footprint were both X Taiwan the our QX, further our we addition
the the peer-reviewed strategic our continued Renuvion clinical regulatory our to portfolio second XXXX, to new we Dermatological of not despite technology. ability our This team the were the materially the do respect two the were to we journal, these Reviews. of featured which pleased in countries to initiative, global efforts both we articles, use While our the progress the reflects expand country continued to of With expect contribute evidence drive either of publication addition of month, to announce COVID. in disruption past supporting performance to due
for when technology used The in first publication evaluated the independently submental liposuction coagulation our neck. of Renuvion
studies, body. when multiple in combination Renuvion treatment sub-dermal we various data publication Each evaluated strengthen for to risk benefit featured used of areas publication The second serves chart profile Renuvion. for believe which liposuction the of with review the coagulation in further retrospective
continue broad-based we its to adoption. and this Renuvion ability progress to on While demonstrate the technology facilitate further recent build of our clinical
for our strategic physician cosmetic to third and Moving surgery initiative, enhancing our support practice customers.
educational the events virtually. impacted Given pandemic ability has COVID continues in-person to team that programming our conduct our host to
by marketing approximately similar sales, the quarter, virtual of our some conducted mentoring events, and During events, were top or physicians. customers. were by which were field physician we traditionally PMP organized These education to third and the led events teams clinical in-person physician our program, X XXX physician that have attended
also further and organized our about were team our on training international technology. the for distributors, three educating benefits Our of which them focused virtual features sessions
also our videos include to In customers procedural available for programming, demand. addition expanded user online existing on to and of are we live pre-recorded that have our our resources webinars, platform experience videos
earlier discussed initiatives, focus one as to in quarters, respect been under our cost important implement strategic this areas I initiative our order with are in Energy have capabilities four most and These handpiece, has manufacturing which launched our manufacturing Advanced new efficiencies, improved prior of of improving to margins our of Lastly, efforts the per-unit reflected process our to this improvements APR year. we in products. reduce
of the the sales. Our larger already margin gross benefiting handpiece financial total improvement as handpiece are APR a becomes results from portion our
long-term the challenges strategy. the respect also me strategic quarter our QX, that, of expect drive ability benefits to continue this our customers, financial over to With third remaining the let progress organization in months demonstrate to discuss to pandemic turn our to effectively with XXXX ongoing We to our beyond. initiative results. continued over COVID call support of fourth their Tara profitability while to our the contributions back, Stepping long-term despite and Tara? driving of
